Cemsidomide EHA data and BMY myeloma validation fuel C4 Therapeutics 18% surge
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $35.58M | $20.76M | $31.10M | $45.78M | $33.20M | $21.38M | $19.36M |
| Cost of Revenue | N/A | $7.74M | N/A | N/A | $78.44M | N/A | $28.59M |
| Gross Profit | $35.58M | $13.02M | $31.10M | $45.78M | $-45.24M | $21.38M | $-9.23M |
| Gross Margin | 100.00% | 62.72% | 100.00% | 100.00% | -136.30% | 100.00% | -47.66% |
| Operating Expenses | $155.20M | $152.05M | $160.63M | $127.92M | $15.20M | $56.83M | $7.16M |
| Operating Income | $-119.61M | $-139.03M | $-129.53M | $-82.13M | $-60.45M | $-35.45M | $-16.39M |
| Operating Margin | -336.15% | -669.84% | -416.56% | -179.39% | -182.10% | -165.81% | -84.64% |
| Net Income | $-105.32M | $-132.49M | $-128.18M | $-83.89M | $-66.33M | $-34.10M | $-15.71M |
| Net Margin | -295.96% | -638.34% | -412.19% | -183.23% | -199.83% | -159.48% | -81.14% |
| EPS (Basic) | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-1.54 | $-0.79 | $-1.06 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |